As a member of the Chugai-Roche Group, Chugai Pharma USA LLC (CPUSA), founded in 1995 in San Diego, CA and currently based in Bedminster, NJ, is committed to the timely development and commercialization of safe and effective drugs for the North American market place. For more than 70 years our parent company, Chugai Pharmaceutical Co. Ltd., has provided high quality, safe and effective drugs to the Japanese and global market place, a heritage that will be continued in North America by CPUSA. As a result of our alliance with F. Hoffmann-La Roche Ltd. in 2002, CPUSA enjoys the resources of a large global conglomerate while preserving the focus and agility of a small local company. CPUSA maintains the same therapeutic focuses as our parent, currently working mainly in the areas of treatments for cardiovascular disease, cancer, metabolic disease and diseases involving inflammation. We are a company of collaborative, committed, talented and experienced people with an unwavering dedication to quality and the highest environmental and ethical standards. We all take great pride in bringing new medicines to market for the benefit of those in need.
At CPUSA, our mission is to contribute local experience, expertise and flexibility to Chugai’s global effort to rapidly develop and market high quality, innovative therapies for the benefit of human health and the maximization of shareholder value; and, to create additional value by emphasizing advancements in specialty indications for the North American market.
David J. Mazzo, PhD; President and CEO
Ellen McDonald; Senior Vice President, Business Operations
Nicholas Pelliccione, PhD; Senior Vice President, Regulatory and Pharmaceutical Sciences
Peter Powchik, MD; Senior Vice President, Clinical Development and Chief Medical Officer
Andrew Rackear, JD; Vice President and General Counsel
Holly Wimer; Vice President, Human Resources
Last Updated: 06-01-2006